Showing results (21-30 of 46) with videos related to
Sort By:
Pageof 5
The Journal of Allergy and Clinical Immunology. in Practice|August 26, 2022
Dupilumab Is Effective in Patients With Moderate-to-Severe Uncontrolled GINA-Defined Type 2 Asthma Irrespective of an Allergic Asthma PhenotypeKlaus F Rabe, J Mark FitzGerald, Eric D Bateman, et al.Journal of Asthma and Allergy|April 5, 2023
Health-Related Quality of Life Impairment Among Patients with Severe Chronic Rhinosinusitis with Nasal Polyps in the SINUS-24 TrialJorge F Maspero, Asif H Khan, Carl Philpott, et al.The Journal of Asthma : Official Journal of the Association for the Care of Asthma|September 6, 2022
Dupilumab efficacy and safety in Latin American patients with uncontrolled, moderate-to-severe asthma: phase 3 LIBERTY ASTHMA QUEST studyJorge F Maspero, Guido Cardona, Patricia Schonffeldt, et al.The Journal of Allergy and Clinical Immunology. in Practice|January 1, 2024
Long-Term Safety of Dupilumab in Patients With Moderate-to-Severe Asthma: TRAVERSE Continuation StudyJorge F Maspero, Anju T Peters, Kenneth R Chapman, et al.The Journal of Allergy and Clinical Immunology|January 10, 2022
Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil countClaus Bachert, Ana R Sousa, Joseph K Han, et al.The Journal of Allergy and Clinical Immunology. in Practice|April 10, 2022
Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid DoseChristian Domingo, Jorge F Maspero, Mario Castro, et al.The Journal of Allergy and Clinical Immunology|January 25, 2024
Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthmaLeonard B Bacharier, Ian D Pavord, Jorge F Maspero, et al.Journal of Asthma and Allergy|March 14, 2023
Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen SensitizationJonathan Corren, David J Jackson, Thomas B Casale, et al.Advances in Therapy|May 5, 2018
Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe AsthmaWilliam W Busse, Jorge F Maspero, Klaus F Rabe, et al.Allergy|April 14, 2023
Assessment of dupilumab in children with moderate-to-severe type 2 asthma with or without evidence of allergic asthmaNikolaos G Papadopoulos, Stanley J Szefler, Leonard B Bacharier, et al.Pageof 5